Indoco Remedies Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Indoco Remedies reported standalone revenue growth of 5.8% year-on-year to Rs 4,081 million in Q1 FY27, with consolidated revenue up 8.2% to Rs 4,662 million. Standalone EBITDA margin expanded to 10.3% from 3.8% a year earlier, aided by cost efficiency measures including a reduction in headcount and fewer manufacturing batches. Management discussed regulatory approvals across its Baddi and Goa facilities, a pending USFDA audit for its sterile plant, and flat performance in European and emerging markets which it attributed to timing and one-off factors.
Indoco Remedies reported standalone net revenues of INR 4,291 million for Q4 FY26, up 25.8% year-on-year, driven by strong growth in international formulations across regulated and emerging markets, while domestic formulations were muted due to a weak season. Standalone EBITDA margin improved to 14.7% from 1% a year earlier. Management also disclosed an agreement to hive off the ophthalmology business in India and Africa to Sunway and discussed receivables growth, debt levels, and an ECB-related forex impact on finance costs.